Clinical Trials Snapshot

Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes

Phase 1 dose-escalation clinical trial to determine the phase 2 dose of autologous TIL 1383I TCR gene-modified T cells using a retrovirus for patients with advanced melanoma.

Phase 1 dose-escalation clinical trial to determine the phase 2 dose of autologous TIL 1383I TCR gene-modified T cells using a retrovirus for patients with advanced melanoma.

    See more from Immuno-Oncology Resource Center